Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Research has shown that testing for PIK3CA levels after taking palbociclib could help predict a progression-free survival, making it the first known biomarker for this therapy

Researchers found that changes in PIK3CA circulating tumour DNA levels can help predict progression-free survival in advanced breast cancer patients receiving palbociclib and fulvestrant

Source  Shutterstock.com